When to buy what, here.
An article joins this feed when it matches these terms. Each one is also a search of its own.
Recursion Pharma launches a $200M equity offering and reports a Sanofi milestone but is rated a Hold on limited near-term catalysts. Click for more on RXRX. - Recursion Pharmaceuticals announced a $200m equity offering and a $10m milestone payment from Sanofi, reflecting operational progress…
Recursion Pharmaceuticals is poised for higher profit growth after this collaboration. Here's why: Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) snapped a three-day winning streak on Thursday, surging as much as 17.9 percent intraday, after Sanofi finally pulled the trigger on the development…
Sanofi has optioned the first development candidate to emerge from its research collaboration with Recursion, the Salt Lake City drug discovery company, triggering a $10 million milestone payment the same morning Recursion priced an oversubscribed $200 million stock offering. “By combining Sanofi’s…
Quiver Quantitative Recursion Pharmaceuticals Jumps After Sanofi Milestone, Clinical Updates, and $200 Million Financing Recursion Pharmaceuticals, SEC, Nasdaq $RXRX Insider Trading Activity $RXRX insiders have traded $RXRX stock on the open market 14 times in the past 6 months. Of those trades, 0 have…
Hefty Ultra Strong with Fabuloso Watermelon Scent Refreshes Cleanups The full Hefty Ultra Strong with Fabuloso Watermelon Scent range includes tall kitchen trash bags (in either pink or white,) 30-gallo large trash bags for heavy-duty messes, as well as medium…
REDARC has acquired Samlex America, a global manufacturer and supplier of power conversion products founded in 1991 with a market footprint spanning more than 90 countries. The acquisition expands REDARC’s North American presence and adds Samlex’s established portfolio of power inverters, inverter…
Earl Berg, Founder & CEO of Samlex America and Anthony Kittel, CEO of REDARC LONSDALE, South Australia, Oct. 15, 2026 (GLOBE NEWSWIRE) -- REDARC has acquired Samlex America, a global manufacturer and supplier of power conversion products founded in 1991 with a market footprint spanning…
www.marketscreener.com announced that Sanofi has optioned the first development candidate from the two companies? multi-program research collaboration The option triggered a $10 million milestone payment to Recursion, bringing total upfront and milestone payments received from Sanofi under the collaboration…
Recursion wins $200M investment, Sanofi milestone (RXRX:NASDAQ) Seeking Alpha Panama7/iStock Editorial via Getty Images Recursion (RXRX) lost more than 4% in the early premarket trading on Thursday after a $200M equity offering from the AI-driven drug discovery firm overshadowed a decision by…
Salt Lake City, UT, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve lives, today announced that Sanofi has optioned the first development candidate from…